-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 12, the CDE official website showed that JNJ-56136379 tablets and JNJ-73763989 injections under Johnson & Johnson were planned to be included in the breakthrough treatment by CDE, and both were used to treat chronic hepatitis B virus infection (HBV)
.
Image source: CDE official website JNJ-56136379 tablet is a capsid protein assembly inhibitor that blocks HBV replication.
It has a dual mechanism of inhibiting the early and late steps of the virus life cycle
.
In the first human trial in clinical phase Ia, JNJ-56136379 showed good safety and tolerability for 28 days, and had effective anti-HBV activity
.
Studies have shown that the drug may be expected to help patients with chronic hepatitis B achieve a functional cure of the infection through limited treatment options
.
JNJ-73763989 injection is a new hepatitis B drug under research developed by targeted RNAi molecular technology
.
Preclinical research results show that the drug can reduce HBsAg, HBeAg and other hepatitis B virus antigens and HBV DNA in hepatitis B mouse models for a long time after 3 doses of the drug
.
The drug is currently in phase II clinical trials.
The results of previous phase I clinical studies conducted in healthy volunteers and patients with chronic hepatitis B showed that the drug was well tolerated.
Only about 11% of the subjects in the trial were injected Mild adverse reactions occurred at the site
.
Hepatitis B (chronic hepatitis B) refers to those who have tested positive for hepatitis B virus, have a course of more than half a year, or have an unclear date of onset, and have clinical manifestations of chronic hepatitis
.
According to the National Health and Medical Commission's Disease Control and Prevention Bureau in 2019, the National Statutory Infectious Diseases Epidemic Situation in 2019, viral hepatitis is still the number B infectious disease with the number of reported cases among the statutory reported infectious diseases in China.
According to estimates, China's hepatitis B virus infection There are about 70 million people, and our country still cannot get rid of the “hepatitis B power” label, and whether hepatitis B can be cured has also become the focus of patients' attention
.
According to Global Data data, it is estimated that by 2020, China's hepatitis B drug market will reach 20 billion yuan, and the long-term market will reach 30 billion.
The market for hepatitis B drugs is still huge and will continue to maintain a high growth trend in the future
.
In China, many pharmaceutical companies are focusing on the hepatitis B track.
For example, the first class of Hausen Pharmaceuticals Hengmu (imitenofovir tablets) has been approved by the National Medical Products Administration (NMPA); Fujian Guangshengtang Pharmaceutical The industry's GST-HG141 has completed phase Ia clinical trials.
The drug is a capsid inhibitor, which can inhibit the uncoating and assembly of hepatitis B virus capsids, and has a good overall safety profile in subjects
.
At the same time, the research immunotherapy BRII-179 (VBI-2601) jointly developed by Tengshengbo Pharmaceutical and VBI Vaccines has also achieved positive results in phase 1b/2a clinical trials for the treatment of patients with chronic hepatitis B virus (HBV) infection.
Result
.
End reference materials: [1] CDE official website [2] https://xueqiu.
com/9766314542/133790156 Past selections of onlookers can really prevent cancer? The 186-country data research has been released.
Insufficient UV exposure or potential causes of colorectal cancer.
Cell releases the global city microbiome map.
Your residence information may be hidden in the shoes.
"Pure drug targets", overcoming the notorious oncogene craze Oxford University: AstraZeneca + Pfizer, is there a "miraculous effect" in the mixed use of the new crown vaccine? Safety is still the most important issue.
The light of hope for cancer patients, and the release of universal targeted drugs can reduce the risk of disease progression and death by 78%! Medical immunotherapy| Biosimilars| Vaccines| Drug resistance| Drug targets| Healthy life| Pharmaceutical company news| Drug inventory| Pharmaceutical technology| Basic research on drug side effects/ Translational medicine leukemia| Lung cancer| Gastric cancer| Colorectal cancer| Liver cancer| Breast Cancer | Pancreatic Cancer | Cardiovascular Diseases | Neurodegenerative Diseases | Intestinal Microbial Medical Devices / Biotechnology In Vitro Diagnosis | Medical Devices | Bio-Nano | 3D Printing | Gene Testing | Single Cell Sequencing | Gene Editing | Assisted Reproduction | Artificial Intelligence | Precision medicine policy anti-cancer drugs | 4+7 volume procurement | Consumables | Filing system | Registrant system | Healthy China | New version of the basic drug catalog | AI medical devices | Telemedicine | Same stock market with different rights/capital IPO | Financing | Cooperation | Funds | Hong Kong Stock Exchange | Science and Technology Innovation Board | Growth Enterprise Market | R & D Investment | Acquisitions | Market & Consumption
.
Image source: CDE official website JNJ-56136379 tablet is a capsid protein assembly inhibitor that blocks HBV replication.
It has a dual mechanism of inhibiting the early and late steps of the virus life cycle
.
In the first human trial in clinical phase Ia, JNJ-56136379 showed good safety and tolerability for 28 days, and had effective anti-HBV activity
.
Studies have shown that the drug may be expected to help patients with chronic hepatitis B achieve a functional cure of the infection through limited treatment options
.
JNJ-73763989 injection is a new hepatitis B drug under research developed by targeted RNAi molecular technology
.
Preclinical research results show that the drug can reduce HBsAg, HBeAg and other hepatitis B virus antigens and HBV DNA in hepatitis B mouse models for a long time after 3 doses of the drug
.
The drug is currently in phase II clinical trials.
The results of previous phase I clinical studies conducted in healthy volunteers and patients with chronic hepatitis B showed that the drug was well tolerated.
Only about 11% of the subjects in the trial were injected Mild adverse reactions occurred at the site
.
Hepatitis B (chronic hepatitis B) refers to those who have tested positive for hepatitis B virus, have a course of more than half a year, or have an unclear date of onset, and have clinical manifestations of chronic hepatitis
.
According to the National Health and Medical Commission's Disease Control and Prevention Bureau in 2019, the National Statutory Infectious Diseases Epidemic Situation in 2019, viral hepatitis is still the number B infectious disease with the number of reported cases among the statutory reported infectious diseases in China.
According to estimates, China's hepatitis B virus infection There are about 70 million people, and our country still cannot get rid of the “hepatitis B power” label, and whether hepatitis B can be cured has also become the focus of patients' attention
.
According to Global Data data, it is estimated that by 2020, China's hepatitis B drug market will reach 20 billion yuan, and the long-term market will reach 30 billion.
The market for hepatitis B drugs is still huge and will continue to maintain a high growth trend in the future
.
In China, many pharmaceutical companies are focusing on the hepatitis B track.
For example, the first class of Hausen Pharmaceuticals Hengmu (imitenofovir tablets) has been approved by the National Medical Products Administration (NMPA); Fujian Guangshengtang Pharmaceutical The industry's GST-HG141 has completed phase Ia clinical trials.
The drug is a capsid inhibitor, which can inhibit the uncoating and assembly of hepatitis B virus capsids, and has a good overall safety profile in subjects
.
At the same time, the research immunotherapy BRII-179 (VBI-2601) jointly developed by Tengshengbo Pharmaceutical and VBI Vaccines has also achieved positive results in phase 1b/2a clinical trials for the treatment of patients with chronic hepatitis B virus (HBV) infection.
Result
.
End reference materials: [1] CDE official website [2] https://xueqiu.
com/9766314542/133790156 Past selections of onlookers can really prevent cancer? The 186-country data research has been released.
Insufficient UV exposure or potential causes of colorectal cancer.
Cell releases the global city microbiome map.
Your residence information may be hidden in the shoes.
"Pure drug targets", overcoming the notorious oncogene craze Oxford University: AstraZeneca + Pfizer, is there a "miraculous effect" in the mixed use of the new crown vaccine? Safety is still the most important issue.
The light of hope for cancer patients, and the release of universal targeted drugs can reduce the risk of disease progression and death by 78%! Medical immunotherapy| Biosimilars| Vaccines| Drug resistance| Drug targets| Healthy life| Pharmaceutical company news| Drug inventory| Pharmaceutical technology| Basic research on drug side effects/ Translational medicine leukemia| Lung cancer| Gastric cancer| Colorectal cancer| Liver cancer| Breast Cancer | Pancreatic Cancer | Cardiovascular Diseases | Neurodegenerative Diseases | Intestinal Microbial Medical Devices / Biotechnology In Vitro Diagnosis | Medical Devices | Bio-Nano | 3D Printing | Gene Testing | Single Cell Sequencing | Gene Editing | Assisted Reproduction | Artificial Intelligence | Precision medicine policy anti-cancer drugs | 4+7 volume procurement | Consumables | Filing system | Registrant system | Healthy China | New version of the basic drug catalog | AI medical devices | Telemedicine | Same stock market with different rights/capital IPO | Financing | Cooperation | Funds | Hong Kong Stock Exchange | Science and Technology Innovation Board | Growth Enterprise Market | R & D Investment | Acquisitions | Market & Consumption
